-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of August 19, the 2021 semi-annual report disclosed by Guoen shares showed that the company achieved operating income of 4.
150 billion yuan in the first half of the year, an increase of 17.
33% year-on-year; net profit attributable to shareholders of listed companies was 352 million yuan.
The reason for the high base last year was a year-on-year decrease of 34.
03%, but compared with the 168 million yuan in 2019, it still achieved a growth that more than doubled
.
It is worth mentioning that in the first half of this year, the company acquired 21.
18% of the shares of another A-share listed company, Dongbao Biotechnology, by participating in fixed increase and share transfer, and became its controlling shareholder.
Guoen is a large-scale industrial platform as the main body, and a dual-industry main body coordinated development model with Guoen Chemical Industry and Dongbao Bio-Healthcare and Beauty Industry as the two wings
.
Up to now, the company has developed into seven major business segments including polymer modified materials, polymer composite materials, medical protective materials, degradable materials, sports lawns, optical (film, sheet) materials, special vehicles and modular houses.
Comprehensive group enterprises such as gelatin and hollow capsules, collagen peptides, plasma substitute gelatin, double protein artificial meat, medicine, health, food, and beauty in the big health industry
.
In the first half of the year, in the large chemical industry, the company continued to strengthen the business of household appliances and consumer electronics, medical protective materials, automobiles and new energy, charging piles, degradable materials, light display materials, sports lawns, etc.
, in the application and promotion of new chemical materials Deepen the aspect and multi-point layout
.
Combining with the development trend of the industry, the company intends to carry out a multi-point layout in the upstream of modified materials in the large chemical industry and fine chemical industry in the future
Among them, under the background of the country's "carbon peak" and "carbon neutral" strategy, bio-based degradable plastics that can achieve a balanced carbon cycle are expected to be vigorously developed
.
As a professional enterprise with many years of experience in the development and production of modified materials, Guoen shares have achieved technological breakthroughs in the field of biodegradable modified materials by using existing technical reserves and capacity advantages:
The company has developed a variety of biodegradable modified materials such as PLA, PBAT, PBS, PPC, and thermoplastic starch plastics.
The application technology includes enhancement, temperature resistance, alloy, biocompatibility and other modification directions, which can be widely used in degradable packaging.
Bags, shopping bags, disposable tableware lunch boxes, hot and cold drink straws, film products and other market directions
.
The product can meet the requirements of EU EN13432 and US ASTMD6400 for full biodegradation testing, and meet the national standard GB31604 food contact material testing requirements
In terms of the big health industry, the company adheres to the industrial idea of integrated development, deploys gelatin, biomedicine, medical beauty, personal care and other sub-sectors in the big health industry, opens up the upstream and downstream of the industry chain, and integrates resources
.
Among them, the collaborative cooperation between subsidiary Yiqing Biology and Dongbao Biology will realize the integration of bone gelatin/fish gelatin industry and realize the coverage of downstream pharmaceutical excipients, health care products, and medical beauty products
In the context of the company’s continued improvement in business operations and steady growth in performance, the company’s third-largest shareholder, the National Social Security Fund 504 Portfolio, increased its position in the first half of the year by 1.
